










































Werner syndrome (WS) is an autosomal recessive 
disorder characterized by premature onset and an 
accelerated rate of development of major geriatric 
diseases, including atherosclerosis, diabetes mellitus, 
osteoporosis, cataract and menopause, and 
predisposition to sarcoma and carcinoma [1]. Atrophy 
of the skin and premature graying of the hair are also 
common in WS patients. The characteristics that define 
WS among several other premature aging syndromes 
are that affected  individuals  show  normal  growth  and  
 
 








































development until adolescence, after which the various 
symptoms appear segmentally in an individual-specific 
manner [2]. The WS gene (WRN) has been mapped to 
the short arm of chromosome 8 [3], and identified as a 
RecQ-type DNA helicase-encoding gene [4]. About 
75% of WS cases have been reported in Japan.  
 
Human somatic cells are known to have a limited 
proliferative life span (the Hayflick limit) when serially 
cultured in vitro [5, 6]. When they approach this limit, 
they cease to replicate and exhibit a state of replicative 
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TTAGGG [7], along with associated proteins [8] 
located at the ends of chromosomes, and is thought to 
protect them from being recognized as broken or fused 
[9]. Decrease of telomeric DNA in human fibroblasts as 
a function of serial passage during in vitro aging was 
first demonstrated by measurement of terminal 
restriction fragment (TRF) length [10]. Subsequently it 
was shown that the proliferative capacity of human 
fibroblasts  in vitro could be extended by transfection 
with the enzyme telomerase [11]. These two lines of 
evidence led to the telomere hypothesis of cellular aging 
[12], which in turn was extrapolated to individual aging. 
However, since human dermal fibroblasts [13], 
epidermis [14] and other tissues [15] of individuals aged 
90-100 years still have TRF lengths of 6-7 kilobase 
pairs (kbp) and retain proliferative capacity for about 20 
doublings, they appear not to have reached the limit of 
their proliferative capacity. Indeed, Cristofalo et al. 
reported that there was no significant decline in the 
proliferative potential of human fibroblasts in vitro with 
age [16]. Hence, recurrent arguments have arisen [17, 
18], and these have still not been settled. 
 
Because of its particular characteristics described above, 
WS has been attracting the attention of gerontologists. 
Initially, before a link between WS and telomere was 
identified, cultured dermal fibroblasts from WS patients 
were found to undergo accelerated rates of decline in 
their replicative potential and to exhibit a variety of 
chromosomal translocations and deletions [19, 20]. 
More recently, the relationship between WRN gene 
deficiency and the telomere has been  investigated 
extensively. TRF length in fibroblasts from individuals 
in the early phase of WS has been shown to be 
comparable with that in cells from normal individuals, 
but that subsequently accelerated TRF shortening 
occurs [21]. B lymphoblastoid cells from WS patients 
demonstrate anomalous increases and decreases of their 
TRF length during long-term culture after being 
transformed by Epstein-Barr virus, but finally fail to 
become immortalized [22]. Although many data have 
been accumulated using in vitro proliferation systems, 
and the notion of accelerated telomere shortening in 
premature aging syndromes has been widely accepted, 
few data on the telomere lengths of cultured cells other 
than dermal fibroblasts and lymphocytes of WS patients 
have been obtained. Furthermore, details of telomere 
shortening in vivo in WS and its relationship to the 
clinical symptoms have been lacking.  
 
In this study, we investigated TRF length in the 
extremities of WS patients at various ages (range: 30 to 
61 yr). All of these patients suffered from skin ulceration, 
which is a common complication of WS [23], and we 
attempted to ascertain whether age-related TRF 
shortening in skin (typical proliferating tissue) and 
muscle (typical post-mitotic tissue) from WS patients 




Histopathological features of tissue samples  
 
We examined 10 epidermal samples collected from 
extremities of 8 WS patients aged between 30 and 61 
years that had been surgically amputated because of skin 
ulceration. Their ethnicity was Japanese. We also analyz-
ed four samples of muscle tissue from the zone adjacent 
to the examined epidermis. Details of the data including 
the genotypes of the patients are shown in Table 1. As 
controls, 56 skin samples and 14 muscle samples from 
autopsy cases unrelated to WS were analyzed. 
 
To define the histopathological characteristics of the 
skin samples, we performed microscopy analyses. 
Figures 1A and B show representative microscopic 
views of the skin tissues from WS patients. The sample 
on the left (A) is a piece of skin tissue from which 
dermal tissue had been removed with a scalpel, and the 
sample on the right (B) is one that was not subjected to 
such treatment. To determine the representative cell 
species in each tissue, we counted the numbers of 
nuclei. The numbers of keratinocytes and non-
keratinocytes (including dermal fibroblasts, capillary 
endothelial cells, and lymphocytes) in section A were 
3.3 × 10
2 (18
2) and 1.2 × 10
2 (11
2), respectively, and 
those in section B were 5.7 × 10
2 (24
2) and 2.2 × 10
2 
(15
2), respectively. Hence, the ratio of keratinocytes to 
non-keratinocytes in the samples from which genomic 
DNA was extracted was 18
3 : 11
3 in (A) and 24
3 : 15
3 in 
(B), thus being approximately 4 : 1 in both cases. 
Similar values were obtained in the other cases of WS. 
Consequently, keratinocytes were considered to be a 
suitable representative cell type for each skin sample. 
With regard to muscle tissues, myocytes were the 
representative cell type. 
 
Assessment of DNA sample quality by pulse-field gel 
electrophoresis  
 
To check the quality of the high-molecular-weight DNA 
samples, all were subjected to  pulse-field gel 
electrophoresis in an undigested state [24] (Figure 2A). 
All samples were longer than 50 kbp, and qualified for 
further TRF analysis.  
 
Southern blot analysis of TRF length in skin 
 
For quantification of telomere lengths,  we  digested  the  
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the restriction enzyme HinfI, and also digested the DNA 
from 8 skin samples from 7 WS patients using the 
restriction enzyme RsaI, and performed Southern blot 
analysis (a representative image is shown in Figure 2B) 
at least three times for each sample. The means of the 
median TRF lengths from WS patients are summarized 
in Table 1. A robust correlation with the paired values 
was observed (not shown), and generally the value of 
HinfI digests was greater than that of RsaI digests. The 
means of the sample values after HinfI and RsaI 
digestion were 11.0 ± 2.0 and 10.4 ± 2.3 kbp, 
respectively. The difference between them was 
significant (p <0.0001). We also digested the DNA from 
control samples using the restriction enzyme HinfI, and 








































With regard to DNA sample quality, the Southern blot 
data obtained from densitometric analysis using the 
Telometric software package demonstrated no 
remarkable signals suggestive of DNA degradation (see 
Supplementary data, Figure S1). 
 
Rates of TRF shortening with aging in skin tissues 
from WS patients and normal controls 
 
The median values of the HinfI-digested TRF lengths 
for 10 WS subjects were plotted as a function of age 
(Figure 3, Supplementary data Figure S2A). The 
median values of the HinfI-digested TRF lengths for 
skin in the 56 non-WS control subjects were also 








































































WS-1 39  M 4/4  lower  leg  ankle +  12.3  11.5  + 14.5 
WS-2  43  M  4/4  lower leg knee  +  13.0  12.3  +  13.3 
WS-3 62  M 6/6  foot  toe  +  8.9  8.0     
WS-4(1) 37  M  4/4 lower  leg  +  11.5  11.1     
WS-4(2) 43  M  4/4 upper  arm  +  12.8  12.1     
WS-5 30  F n.d.
e upper  arm  +  13.2  12.2     
WS-6 42  F  4/4  wrist  +  10.5       
WS-7(1) 41  M  1/4 lower  leg  +  11.1  10.4  +  10.1 
WS-7(2) 44  M  1/4 lower  leg  +  9.2    +  8.5 









































































































































shows  a  size  marker.  In  the  WS‐4  and  WS‐7  patients,  skin  samples  were  collected  twice  at  different  ages  (see  Table  1).
Corresponding relative copy number profiles calculated by the Telometric program are shown as Supplementary data (Figure S1) 
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and control groups, we applied a multiple regression 
model that related Y (TRF length) to X1 (age) and X2 
(group), given that the WS group was 1 and the control 
group 0: Y = β0 + β1X1(age)+ β2 X2(group). Since the 
WS patient group did not include neonates and young 
adults or very elderly individuals, we carried out the 
analysis using a non-WS control group, omitting 
neonates, infants, juveniles and the very elderly (n = 21, 
aged between 30 years and 80 years). This model 
yielded a regression line indicating that the average 
annual rate of telomere shortening (β1) was 139 bp (p 
<0.0001) and that the difference between the WS and 
control groups (β2) was -3.6 kbp, the group effect being 
significant (p = 0.00026) (Figure 3). Since the 
difference in the TRF values of 3.6 kbp between the 
control and WS groups was equal to 0.139 kbp (annual 
reduction rate)×26 (years), this difference indicated that 
the TRF lengths in WS patients were equivalent to those 
in control individuals who were 26 years older.   
                   
To assess the TRF attrition rate in each group, we also 
applied a simple regression model relating Y (TRF 
length) to X (age): Y = β0+  β1(X). This yielded a 
regression line indicating that the average annual rate of 






























bp (p = 0.0047) (Supplementary data, Figure S2A). The  
RsaI-digested samples were also analyzed in the same 
way, and this showed that the average annual rate of 
TRF reduction was 178 bp (p = 0.0048) (Supplementary 
data, Figure S2B). Intriguingly, comparison of the two 
sets of data from the same individuals at different ages, 
cases WS-4 and WS-7, revealed that in WS-7 the TRF 
length decreased as a function of age (-1.9 kbp/3 years), 
whereas in WS-4 the TRF length increased as a function 
of age (+1.3 kbp/5 years).  
      
TRF length in muscle tissues from WS patients and 
normal controls  
 
We next analyzed the TRF lengths of the HinfI 
digested-DNA samples of muscle tissues from 4 WS 
patients (shown in Table 1) and control patients 
(shown in Table S2). The mean of the 4 median values 
was 11.4 ± 1.0 kbp. The median values of the HinfI-
digested TRF lengths in muscle tissue from 4 WS 
patients and a control (n = 14) were plotted as a 
function of age (Figure 4). Multiple regression 
analysis yielded a regression line: Y = 14.6 – 0.010 
(X) – 2.6 (group). The TRF lengths in the WS group 
were significantly shorter than those in the control 




























































TRF length measurement by Southern blotting is 
hampered by the fact that the presence of other cell 
types always hinders accurate assessment of telomere 
length in the context of a specific cell type in tissues or 
organs [25, 26, 27]. In the present study, we separated 
intact skin tissues from areas showing overt ulceration 
containing many inflammatory cells, and removed as 
much connective tissue adjacent to the epidermis as 
possible. On the basis of histological examination, we 
confirmed that approximately 80% of each DNA 
sample was derived from epidermal keratinocytes. 
Previous studies have employed a variety of methods 
for detection and calculation of TRF values. The annual 
telomere reduction rate in normal skin was first reported 
to be 19.8 bp based on the peak values obtained from 
densitometric images of TRF [26]. In the present study, 
we used the software package Telometric and the 
median TRF values as representatives. The annual TRF 
reduction rate in the normal controls was 40 bp, which 
was reasonably compatible with the value of 36 bp 
obtained in our previous study, in which we used the 
peak values as representatives [14]. 
 
TRF length in every organ of each individual was 
originally considered to be approximately the same at 
birth [28], but subsequent measurements of TRF length 
in cerebral cortex and myocardium showed that it is 


























mean TRF length of human systemic organs has been 
reported to be approximately 13 ± 2 kbp at birth [15, 14, 
29]. Since young WS patients are usually quite healthy 
and have no evident disease [1], it is very difficult to 
obtain tissues and organs from them. In fact, we were 
unable to examine TRF lengths in neonatal/infant WS 
patients, and no data are available in the literature. In 
view of this situation, the neonatal TRF values for skin 
in WS patients derived from regression analyses (17.1 
kbp based on multiple regression and 18.2 kbp based on 
simple regression) would seem to be implausible 
(Figure 3, Figure S2A).  
 
With regard to telomere length dynamics in vivo, it has 
been reported that telomere loss is rapid in the young, 
but shows slow reduction in the elderly [30, 31, 25]. A 
longitudinal study of leukocytes from newborn baboons 
using quantitative fluorescence in situ hybridization has 
provided definitive proof of rapid telomere loss during 
the very early infant stage [32]. In contrast, our studies 
have demonstrated that the TRF length in epidermis is 
well maintained up to middle age (40s –50s), and then 
gradually decreases. We consider that one of the major 
causes of this epidermis-specific telomere dynamic is 
retention of a considerable amount of telomerase 
activity even in adult epidermal tissue [14]. The profile 
for WS epidermis also seems to resemble the normal 
one, except that the time scale is shortened by 
approximately 25 years (Figure 3). Regarding 
contradiction of the two sets of data from the same 
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 individuals at different ages, cases WS-4 and WS-7, the 
mechanisms was unrevealed but such anomalous up and 
down of telomere length seems to resemble the 
phenomena observed in Epstein-Barr virus transformed 
B lymphoblastoid cells derived from WS patients [22]. 
Such anomalous telomere dynamics may universally 
occur in WS patients segmentally. Contrary to skin, 
muscle samples demonstrated a flat regression line, 
suggested that the muscle TRF values for neonatal WS 
patients are well maintained and typical of a post-
mitotic tissue during the period from childhood to 
adulthood. Hence, in some WS patients, the TRF values 
could be extremely short even at a very early age. 
 
Cultured fibroblasts from WS patients are characterized 
by slow growth rates, premature senescence, accelerated 
telomere shortening and genomic instability [19, 20, 21, 
33, 34]. Despite the greater loss of TRF length in 
cultured cells, it has been reported that the mean TRF 
lengths of cultured cells from 4 WS patients at earliest 
passage and senescencewere not shorter than those from 
4 normal subjects [21]. Another report has indicated 
that the TRF length in fibroblasts from a WS patient 
was shorter than in any of 5 controls subjects examined 
[35]. Baird et al. demonstrated telomere shortening at 
the chromosome arm level using a PCR-based method 
in bulk-cultured normal and WS fibroblasts of 99 and 
355 bp per PDL, respectively. Data for cloned lines 
showed that the difference between WS and normal 
controls was not significant [36]. On the other hand, it 
has been shown that overexpression of telomerase 
(hTERT) in WS fibroblast cell lines partially rescues 
then from accelerated cell senescence [37] and restores 
genomic stability [38], indicating that one of the 
consequences of the WS defect is acceleration of 
normal telomere-driven replicative senescence. It has 
also been reported that only telomeres replicated by 
lagging strand synthesis are affected in cells lacking 
WRN [39]. The relationship between this novel 
topological specificity of the enzyme and accelerated 
telomere erosion remains to be clarified. In addition, the 
WRN gene product has been shown to have a novel 
function other than helicase activity, exonuclease 
activity [40]. Furthermore, not only the WRN gene per 
se but also combined functions with various associated 
molecules, including shelterin (e.g. TRF1, TRF2, 
POT1) [8, 40] and Flap endonuclease 1 [41, 42], have 
been shown to be important in telomere metabolism. 
Recently, it has been reported that Rap1, a member of 
the shelterin complex, functions in genome-wide 
transcriptional regulation and NF-￿B-dependent 
signaling [43, 44, 45]. These findings appear to provide 
a novel perspective of the relationship between 
extraordinary telomere shortening and the complex 
symptoms of WS. Our present study has surveyed most 
expanded WS individuals ever, was partly concordant 
with previous in vitro studies described above, 
especially the study by Shulz et al. [21] and the bulk-
cultured cell data by Baird et al. [36]. Our finding that 
the TRF lengths in both skin and muscle from WS 
individuals of the same generation were distributed over 
a wide range suggest that TRF lengths in WS might be 
characteristic to each patient, as is the case in normal 
individuals [15]. The distinctive decrease of TRF 
lengths in skin and muscle from WS individuals also 
indicated a tissue-specific effect of WRN on telomere 
maintenance.  
 
To date, the only in vivo study of the relationship 
between a premature ageing syndrome and accelerated 
telomere attrition was considered to be one 
demonstrating accelerated TRF shortening in 
lymphocytes from patients with Down syndrome 
relative to age-matched controls [46]. Comparison of 
those findings with our present data revealed some 
intriguing similarities. Although both sets of data were 
based on a limited number of samples, several 
interpretations are possible. If we postulate that there 
are no differences of TRF length in the early period 
between Down syndrome and controls, the respective 
attrition rates and likely explanations could differ. On 
the other hand, relationships between various progeroid 
phenomena and defective telomere metabolism have 
been reported in patients with dyskeratosis congenita, 
who have mutations of dyskerin or the RNA component 
of the telomerase gene [47, 48, 49]. Our data suggest an 
intriguing difference between dyskeratosis congenita 
and WS, the former affecting mainly proliferating 
tissues, whereas the latter affects not only proliferating 
but also post-mitotic tissues. Comparison of these 
diseases with WS might provide indispensable 
information. 
 
Since all of the WS patients examined in this study 
suffered skin ulceration and showed variable TRF 
lengths, and younger patients in particular possessed 
TRF lengths compatible with those in the controls, our 
data did not support telomere shortening in the 
epidermis as a trigger for the symptoms, and suggested 
that other pathological cause(s) due to defective WRN 
might play a more significant role in the onset of skin 
ulceration in WS. Our data demonstrated that such 
telomere shortening occurred not only in a typical 
proliferating tissue, epidermis, but also in a post-mitotic 
tissue derived from mesoderm, muscle. This finding is 
of particular interest in view of the extraordinarily high 
incidence of sarcoma at an early age and that of 
carcinoma at advanced age in WS patients. 
Understanding the role of single-gene deficiency in the 
aging process, such as that in WS, could yield valuable 
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fundamental data that can serve as a basis for reviewing 
previously accumulated findings based on in vitro 
cellular analyses from a different perspective.  
 
MATERIALS AND METHODS 
 
Subjects.  Skin samples from 8 Japanese WS patients 
were analyzed. Since single samples were obtained 
from 6 patients and 2 samples from 2 patients (WS-4, 
WS-7) at different ages, a total of 10 samples were 
analyzed. All of the skin samples were obtained from 
extremities that had been amputated due to severe skin 
ulceration. We also analyzed 4 samples of muscle tissue 
from the zone adjacent to the examined epidermis. 
Details of the data including the genotypes of the 8 
patients are shown in Table 1. As controls from autopsy 
cases unrelated to WS, 56 skin samples aged between 0 
and 101 and 14 muscle samples aged between 0 and 69 
years were analyzed (summarized in Table S1 and 
Table S2, respectively). The study protocol was 
approved by the Ethics Committee of Tokyo 
Metropolitan Institute of Gerontology. 
 
Preparation and histopathological examination of 
tissues.  The dermis was carefully removed with a 
scalpel as cleanly as possible from the skin tissues. The 
tissues samples were examined histopathologically by 
specialists in anatomical and surgical pathology (K. T., 
N.I., J.A., Y. I.), and the nuclei were counted.  
 
Isolation and examination of DNA. Genomic DNA was 
prepared by the standard method with proteinase K and 
sodium dodecyl sulfate, followed by repeated manual 
extraction with phenol-chloroform as gently as possible. 
 
Genomic DNA from all samples was examined their 
quality by pulse-field gel electrophoresis [24], as 
described previously [14]. Briefly, they were subjected 
to the Genofield system (ATTO, Tokyo, Japan), a 
biased sinusoidal field gel electrophoresis system. 
 
Measurement of TRF length by Southern blotting. We 
used the standard method to measure TRF length, as 
described previously [14]. Briefly, a 5-μg sample of 
DNA was digested with the restriction enzyme HinfI or 
RsaI (Roche Diagnostics, Germany). TRF was 
visualized with a (TTAGGG)4 probe labeled with [γ-
32P]ATP. The TRF image was analyzed using a BAS-
2500 Mac image analyzer (Fuji Photo Film) and the 
Image Reader program (version 1.1, Fuji Photo Film). 
Representative values of TRF length (median, mean, 
mode, SIR) were determined using the Telometric 
software package [50]. 
 
Statistical analyses.  Differences in the values were 
assessed for significance by Student’s t test. 
Relationships between TRF length and age were 
assessed by simple regression analyses, and 
relationships among TRF length, age and group (WS 
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for  the  patients  overall  were  located  under  control  line‐2.  (B)  By  simple  regression  analysis,  we 
obtained a regression line for the RsaI‐digested TRF length for 7 WS patients (8 samples) (p =0.0048). 
   


























































































































Patient Age  Sex
a TRF  length
b  Cause of death
d 
ID [years]    of  skin
c [kbp]   
1 0  M 13.9   
2 0  F  13.1   
3 0  M 11.1  13  trisomy 
4 0  M 12.7   
5 0  F  12.5   
6 0  F  12.8   
7 0  F  12.7   
8 0  F  14.0   
9 0  F  13.5   
10 0 F  14.1   
11 0  M  13.9   
12 0  M  13.6   
13 4 F  12.1   
14 18  M  10.6   
15  18  M  11.9  Malignant melanoma of meninx 
16  33  M  14.0  Colon cancer, Pancreatic cancer 
17 48  M  13.8   
18 51 F  17.0  Cerebral  infarction 
19 53 F  14.7  Ovarian  cancer 
20 58  M  11.8  Lung  cancer 
21 59  M  12.4  Gastric  cancer 
22 61  M  10.2   
23 68 F  11.7   
24 68  M  11.3  Myocardial  infarction 
25 69  M  10.5   
26 71  M  11.6  Alcoholic  liver  cirrhosis 
27 74  M  9.8  Sepsis 
28 75  M  7.2  Gastric  cancer 
29 75 F  11.0  Liver  cirrhosis 
30 75 F  10.5  Myelodysplastic  syndrome 
31 76 F  12.2  Pneumonia 
32 76 F  8.8   
33 77 F  13.1  Aspiration  pneumonia 
34 78  M  12.2  Acute  myelogenous  leukemia 
35 78 F  8.3   
36 79  M  7.6  Acute  myeloblastic  leukemia 
37 81 F  11.1  Malignant  lymphoma 
38 82 F  8.2  Acute  myelogenous  leukemia 
39  83  F  10.0  Adult T cell leukemia 
40  83  F  9.7  Motor neuron disease 
41 84  M  10.0  Gastric  cancer 
42 84 F  7.6  Myocardial  infarction 
43 85 F  9.2  Brain  hemorrhage 
44 85 F  11.0  Gastric  cancer 
45  85  F  10.3  Cancer of gall bladder 
46  85  M  10.1  Cancer of papilla Vateri 
47 86 F  9.1  Colon  cancer 
48  88  F  10.2  Rupture of aneurysm 
49 88 F  9.8  Cerebrovascular  diseases 
50  89  F  11.7  Rupture of aneurysm 
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51 92 F  9.0  Malignant  lymphoma 
52 94 F  8.8  Pneumonia 
53 94 F  9.1  Aortic  stenosis 
54 97 F  9.4  Aspiration  pneumonia 
55  100  M  7.5  Chronic obstructive lung disease 


























1 0  F  15.4   
2 0  M  11.2  13trisomy 
3 0  M  16.0   
4 0  M  14.2   
5 0.3  F  16.1   
6  18  M  14.2  Malignant melanoma of meninx 
7  33  M  13.5  Colon cancer, Pancreatic cancer 
8 50  M  12.7  Interstitial  pneumonia 
9 51  F  17.7  Cerebral  infarction 
10 53  F  14.7  Ovarian  cancer 
11 58  M  11.8  Lung  cancer 
12 59  M  14.7  Gastric  cancer 
13 66  M  15.0  Brain  hemorrhage 
14 69  M  12.5  Subarachnoideal  hemorrhage 
a. F: woman, M: man. 
b. Median value of TRF was used as representative. 
c. Samples of muscle tissue were obtained from skeletal muscle of thigh. 
d. Diagnosis at autopsy. 